Animal Model of Dermatophytosis by Shimamura, Tsuyoshi et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2012, Article ID 125384, 11 pages
doi:10.1155/2012/125384
Review Article
Animal Model of Dermatophytosis
Tsuyoshi Shimamura,1,2 Nobuo Kubota,1 and Kazutoshi Shibuya2,3
1R&D Laboratories, POLA Pharma Inc, 560 Kashio-cho, Totsuka-ku, Yokohama 244-0812, Japan
2Department of Surgical Pathology, Toho University School of Medicine, 6-11-1 Omori-Nishi, Ota-Ku, Tokyo 143-8541, Japan
3Department of Dermatology, Peking University First Hospital, Beijing 100034, China
Correspondence should be addressed to Kazutoshi Shibuya, kaz@med.toho-u.ac.jp
Received 9 December 2011; Revised 8 February 2012; Accepted 13 February 2012
Academic Editor: Monica Fedele
Copyright © 2012 Tsuyoshi Shimamura et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Dermatophytosisissuperﬁcialfungalinfectioncausedbydermatophytesthatinvadethekeratinizedtissueofhumansandanimals.
Lesionsfromdermatophytosisexhibitaninﬂammatoryreactioninducedtoeliminatetheinvadingfungibyusingthehost’snormal
immune function. Many scientists have attempted to establish an experimental animal model to elucidate the pathogenesis of
human dermatophytosis and evaluate drug eﬃcacy. However, current animal models have several issues. In the present paper, we
surveyed reports about the methodology of the dermatophytosis animal model for tinea corporis, tinea pedis, and tinea unguium
and discussed future prospects.
1.Introduction
Superﬁcial mycoses aﬀect 20% to 25% of the world’s popula-
tion, and the incidence is increasing [1]. However, the mech-
anisms of the characteristic pathology, the mechanisms of
host protection against infection, and the reason for intract-
able tinea pedis have not been clariﬁed. Thus, experiments
to elucidate these questions regarding dermatophytosis are
needed using an animal model that closely resembles human
pathology.
However, the suggestion has been made that the model
ofexperimentalinfectiononthebacksofanimalswasinsuﬃ-
cienttoclarifythepathologyoftineacorporisandtineapedis
because the site of infection was as severe as in kerion celsi,
and the treatment duration was limited due to spontaneous
healing within 4 weeks after infection [2]. Concerning ony-
chomycosis, tinea unguium research in humans has not pro-
gressed due to the inability to biopsy nails. And the patho-
genesis and the invasion have not been fully understood.
Thus, there are few reports of a model of onychomycosis
because of the diﬃculty in setting up a model.
In this paper, we surveyed the reported animal models
of tinea corporis, tinea pedis, and tinea unguium and will
discuss the future direction of research to establish a der-
matophytosis animal model with high reproducibility for
human dermatophytosis.
2. AnimalModel of Tinea Corporis
Tinea corporis in humans is mainly caused by Trichophyton
rubrum, Trichophyton mentagrophytes,a n dMicrosporum
canis and take several clinical forms but commonly present
as classic ringworm [3]. Ringworm of the body is usually
observed on the trunk, shoulders, or limbs, and occasionally
the face (excluding the beard area). The infection may range
from mild to severe, commonly appearing as annular, scaly
patches with sharply marginated, raised erythematous vesic-
ular borders [4].
The eﬀorts to establish an animal model of tinea corporis
began with the ﬁrst report by Bloch in 1908 [5]. Sakai et al.
[6] were the ﬁrst to report of animal studies evaluating the
eﬃcacy of tinea corporis, and the research became the basis
for the tinea corporis model. Subsequently, many research
studieshavebeenreportedananimalmodeloftineacorporis
since 1962. To reproduce dermatophytosis in humans, the
examination of methods using animal models mainly fo-
cused on animal species, fungal selection, and the condition
oftheinfection(occlusionoropenconditionwithorwithout
abrasion) of the skin.
2.1. Animal Species. The tinea corporis model has been
reported in a variety of diﬀerent animals, such as cockscomb2 Journal of Biomedicine and Biotechnology
[7], germ-free guinea pigs [8], grafting guinea pig skin onto
congenitally athymic mice [9], mice [10], nude rats [11, 12],
rabbits[13], chickens [13], humans [14–16], and guinea pigs
[6, 7, 9, 10, 12, 13, 17–60].
According to reports of T. mentagrophytes on cockscomb
and guinea pigs [7], the skin of guinea pigs showed a greater
resemblance to human skin; however, cockscomb was more
suitable than the skin of guinea pigs for fungal growth.
Nonetheless, topical treatment of cockscomb with drugs is
diﬃcult, especially a ﬂuid excipient.
In germfree guinea pigs infected with T. mentagrophytes,
forming serious ulcers took twice the time as healing com-
pared with conventionally reared guinea pigs. Cutaneous
reinfection of germfree guinea pigs with T. mentagrophytes
was protracted. However, the lesions healed in about the
same time as the primary infection in conventionally reared
guinea pigs. These reactions were considered cell-mediated
hypersensitivity similar to contact dermatitis [8]. Thus, no
advantage was gained in using germfree guinea pigs as the
animal model for tinea corporis because tinea corporis in
humans shows no spontaneous healing.
The in vivo model using nude mice xenografted with
guinea pig skin showed well-grown dermatophytosis on the
xenograft but not on nude mouse skin [9]. On the other
hand, T. mentagrophytes could be cultured from the skin of
nude rats (rnu/rnu) for 90 days and euthymic rats (rnu/+)
for 35 days [11].Inthesestudies, the samestrainof T. menta-
grophytes ATCC18748 was used. Thus, this diﬀerence in the
infection period between nude mice and nude rats was not
due to the organism. We suggest that this diﬀerence involved
the diﬀerent structures of the skin. Fujita [61]r e p o r t e d
that hairless guinea pigs whose skin resembled human hair-
bearing skin could be induced to show clinical signs similar
to human hair-bearing skin lesions and suggested that the
diﬀerence in the skin structure, especially the density of
hair and the thickness of the horny cell layer, aﬀected the
establishment of the infection.
Infectivity of two strains of human origin, Trichophyton
quinckeanum NCPF309 and T. mentagrophytes MRL 81/889,
were evaluated in seven inbred strain mice: BALB/c, AKR,
C3H, DBA/2, (CBA×DBA/2)F1,C B A ,a n dC 5 7 B L / 6[ 10]. As
a result, variations were noted in susceptibility in diﬀerent
inbred mice strains, and BALB/c mice showed greater sus-
ceptibility to the infection from both fungal strains.
Ringworm lesions developed in rabbits infected with
T. mentagrophytes B32663 (dog origin) after intravenous
administration in the same manner as lesions that developed
after percutaneous administration [13].
In experimental infections of humans [15], T. mentagro-
phytes ATCC18748 was applied to the ankles followed by 4-
day-continuous occlusion. The time course of the disease
was described in ﬁne details as follows. (1) During the ﬁrst
2 days following removal of the occlusive patches, no signs
of infection were present. (2) Erythema, edema, and small
vesicles appeared and the degree of inﬂammation steadily
increased from the 3rd to the 10th days. (3) The lesions
enlarged to ﬁll nearly the entire area originally overlain by
the occlusive patch from the 11th to the 22nd days. (4) The
erythema and edema were replaced by scaling, and discrete
follicular infections became apparent from the 23rd to the
45th days. (5) Finally, the infections healed spontaneously
from the 46th to the 90th days. Furthermore, the volar
surface of the forearm was infected using the same method.
Pathological changes were the same as the lesions on the
ankles. However, the whole infection period was shortened,
and the lesions ﬁnally healed spontaneously within 60 days.
The sustainability of lesions may involve the skin structure
as well as immunity because involvement of immunity on
sustainability of the disease in nude rats (rnu/rnu)w a sc l e a r
from the diﬀerence in the duration of complete healing using
euthymic rats (rnu/+) [11].
Guinea pigs have been widely used as a model due to
reproducibility, high susceptibility, and its easy handling.
However, diﬀerent studies have been attempted because of
the suggestion that there were defects wherein the clinical
signs and the course of the pathology have not been similar
to that of humans [62].
2.2. Selection of Fungi. In the preparation of a guinea pig
model, the following fungi were examined: T. mentagro-
phytes,Trichophytonmentagrophytesvar.quinckeanum(mice,
T. mentagrophytes is synonymous), Trichophyton mentagro-
phytes var. granulosum (rodents, now designated Trichophy-
ton interdigitale), Trichophyton mentagrophytes var. men-
tagrophytes (now designated T. interdigitale), Trichophyton
mentagrophytes var. erinacei (hedgehog), Trichophyton verru-
cosum(cattle,horse),T. rubrum (anthropophilic),Trichophy-
ton tonsurans (anthropophilic), Trichophyton asteroids, Tri-
chophyton violaceum (anthropophilic), Trichophyton concen-
tricum (anthropophilic), M. canis, Microsporum gypseum,
Microsporum pesicolor, Candida albicans,a n dEpidermophy-
ton ﬂoccosum. In general, zoophilic dermatophytes are more
pathogenictolaboratoryanimalsthananthropophilicstrains
[63, 64]. Thus, T. mentagrophytes and M. canis were specially
used for the study of susceptibility to infection [2, 61, 63].
2.3. Pre- and Posttreatment. In addition to the selection of
fungi,pre-orposttreatmentincludedocclusionandabrasion
[23, 34, 37, 38, 42, 47, 51, 56]. Each occlusion method after
inoculation of fungi was reported as follows: covered with
ointment [56], covered by a sheet of polyethylene ﬁlm with
an impermeable plastic tape for 24hr [34], moistened gauze
pad with Teﬂon between 24hr and 72hr [38, 39, 42], covered
with a glass ﬁber ﬁlter [37], or covered with a chamber [51].
The occlusion method was suitable for the tinea corporis
model because it was closer to natural infection and achieved
high reproducibility [61]. On the other hand, Kerbs et al.
reported that the occlusive method had not been imple-
mented in the guinea pig model with T. mentagrophytes
ATCC18748 because occlusion treatment weakened the
infection [42]. Furthermore, Saunte et al. [51] suggested that
inoculation under occlusion showed no advantage in the
establishmentofexperimentalinfections.Inconsiderationof
these reports, we should consider the need for occlusion to
infect fungi according to the procedure and fungal strains.
While there are some reports using nonabraded skin
without occlusion [44, 53, 55], abraded skin was used inJournal of Biomedicine and Biotechnology 3
many experiments to secure a high infection rate. The meth-
ods of abrading back skin include the use of sandpaper [22,
23, 25, 31, 33, 45, 47, 48, 54, 58], a roughened pestle [40, 41],
a steel brush [50], pumice stone [17], shaving [51, 57, 59],
and tape stripping [21, 26–30, 32, 35, 36, 46, 51, 52]. The
abrasion techniques using sandpaper, a roughened pestle,
and a pumice stone are simple and easy; however, such
techniques may lead to skin wounds such as an ulcer, which
subsequently can be confused with lesions produced during
dermatophyte infections [51]. Meanwhile, shaving and tape
strippingavoidstheproblemofcreatingulcersbyanartiﬁcial
procedure and can make the skin equally and superﬁcially
traumatized prior to inoculation [51]. In addition, Saunte et
al. stated that pretreatment, such as shaving with a razor or
tape stripping, did not inﬂuence the nature of the infection
by M. canis [51].
2.4. Inoculation Size. An animal model using the occlusion
method without abrasion may be made with a small amount
of fungi (100 spores/3.8cm2)[ 39, 42]. One report stated that
the optimal conditions for dermatophytosis in guinea pigs
were found to be an inoculum of 107 fungal cells applied to
abraded skin without occlusion and that of 108 fungal cells
induced severe lesions [47]. In almost all cases, the inoculum
of 107 fungal cells was applied to the area of infection made
by dermatophytosis in vivo by all kinds of abrasion methods
without occlusion.
2.5. Preparation Method of Tinea Corporis in Guinea Pigs
Model. The typical methods of infection using T. mentagro-
phytes are described below, which summarized the results
from a survey of the literature.
The nonocclusion method involved removing the back
hair of guinea pigs from the entire surface of the skin with
electric hair clippers and then preparing the inoculation site.
Next, the skin was abraded by applying and removing adhe-
sive tape three or four times, shaving the infection area using
a razor, or abrasion with sandpaper, a roughened pestle, a
steel brush, or a pumice stone. After pre-treatment to create
an abrasion, the skin was inoculated by applying a volume of
50–100µLo fT. mentagrophytes 106 cells/mL. However, the
application volume must be changed according to the area.
The occlusion method involved applying 100 cells/site
to a section of the skin to induce an infection [39, 42]a n d
did not include the abrasion procedure [2]. The duration of
o c c l u s i o nw a ss e tf r o m2 4h rt o7 2h r[ 34, 37–39, 51].
2.6. Pathology of Tinea Corporis in Guinea Pig Model. The
pathophysiologic changes over time as a model of infection
in the guinea pig showed that the normal evolution of der-
matophytosis may be clearly divided into four phases [63]:
incubation phase, spreading phase, inﬂammation phase, and
healing or cleaning phase extending from days 25 to 60.
The length of each phase depends on the mode of infection,
fungal species, and strain [63].
Fujita [61] described the pathophysiology of changes
over time focusing on the biological responses of guinea pigs
infected with T. mentagrophytes as the tinea corporis model.
Brieﬂy, erythema and red papules appeared between 4 and 6
days after inoculation, and then the reaction to trichophytin
was positive between 7 and 8 days. This positive reaction to
trichophytin indicated the establishment of cellular immu-
nity to T. mentagrophytes. Therefore, the erythema and
papules gradually increased in size and then fused together.
The lesions that climaxed at 14-15 days showed inﬁltrative
plaque-like erythema with thick scale and crusts. Subse-
quently, these eruptions gradually disappeared and almost
healed spontaneously within 4 weeks after inoculation.
Another report by Koga [64] described the pathophysiologic
changes over time as almost the same as stated above. Fur-
thermore, Koga reported histopathological changes in detail:
no ﬁndings except slight acanthosis thought to be formed by
abrasion on the 3rd day after inoculation. Fungal elements
were only conﬁrmed in the horny cell layer of the epidermis
and epithelium of the follicular infundibulum. Acanthosis
and hyperkeratosis were noted over the entire surface of the
skin, and vasodilatation and inﬂammatory cell inﬁltration in
the upper layer of the dermis were observed on the 7th day.
In addition, there was a large amount of hyphae in the horny
cell layer of the epidermis. On the 14th day, spongiosis was
observed along with severe inﬂammatory cell inﬁltration in
thedermis,however,hyphaewerepresentonlyinthefollicles
and not in the horny cell layer of the epidermis. This disap-
pearance of hyphae in the horny cell layer of the epidermis
was understood as a result of exclusion by increased skin
turnover. In addition, hyphae in the follicles were excluded
before and after the 20th day as part of spontaneous healing.
2.7. Evaluation of Treatment and Prophylaxis by Tinea Cor-
poris Model. The tinea corporis animal model was used to
estimate the eﬃcacy of antifungal agents like bifonazole [21,
22, 25, 26, 35, 46, 52], clotrimazole [22, 23, 25, 35, 37, 40,
46, 52], miconazole [37, 44], tolnaftate [12, 22, 25, 37, 40],
griseofulvin [28, 29, 37, 40, 65], ketoconazole [12, 18, 20,
29, 37, 40], omoconazole [32, 36], terbinaﬁne [26, 29, 40,
41, 47, 48, 50, 58, 65], econazole [40], butenaﬁne [22, 23,
33], naftiﬁne [22], itraconazole [20, 27, 41, 50, 51, 59, 65],
amorolﬁne [21, 65], sertaconazole [44], saperconazole [24],
latoconazole [25], ﬂuconazole [27, 28, 31, 41, 65], SCH
39304 [31, 54], lanoconazole [30, 33, 48], mupirocin [18],
laudamonium[17],KP-103[33],neticonazole[33],R126638
[59], voriconazole [57], ciclopirox [58], pramiconazole [50],
luliconazole [48], and Astragalus verus Olivier [45].
In general, the timing of the start with oral or topical
administration of antifungal agents is when the primary
lesion begins to occur in each model or experiment. In most
cases, the time is from 3–5 days after infection. In a recent
study, Ghannoum et al. [47] started oral treatment of terbin-
aﬁne on the day of infection considering pharmacokinetics.
That is, the start of oral therapy with terbinaﬁne was set to
allow the drug to be absorbed by the gastrointestinal tract
and to reach the tissue by the time the infection was estab-
lished.
The prophylaxis eﬀect of antifungal agents was evaluated
in the tinea corporis model. There was a wide range in the
start of administration between 5 days before infection and4 Journal of Biomedicine and Biotechnology
30 minutes after infection [12, 17, 22, 41, 59]. A clear
rationale for when to start administration has not been
described in detail in these reports. However, the start of
administration and the duration of treatment should be set
to consider the local skin pharmacokinetics of the drug.
Although relapse after treatment was reported [33], exam-
inations have not often been conducted because of sponta-
neous healing in the guinea pigs.
3.AnimalModel of TineaPedis
The feet, especially the soles and toe webs, are the most
frequent site of tinea pedis in humans. The most common
clinical manifestation is intertriginous dermatitis, which
presents with maceration, peeling, and ﬁssuring in the
spaces between the fourth and ﬁfth toes. Another common
presentation is the chronic, squamous, hyperkeratotic type
in which ﬁne silvery scales cover the pinkish skin of the
soles, heels, and sides of the foot (moccasin foot). An acute
inﬂammatory condition characterized by the formation of
vesicles, pustules, and sometimes bullae is most frequently
caused by T. mentagrophytes. The more chronic agents of
tinea pedis is caused by T. rubrum, T. mentagrophytes var.
interdigitale,a n dE. ﬂoccosum [4].
Fujita and Matsuyama reported an animal model of
tinea pedis using a paper disk [66]. Meanwhile, Uchida and
Yamaguchi reported another animal model using a sheer
adhesive bandage [67]. These two animal models of tinea
pedisinguineapigsaresuperiorbecausetheyshowedclinical
and histopathological nonspontaneous healing similar to
human hyperkeratotic tinea pedis.
3.1. Selection of Fungi. In the ﬁrst report on the establish-
ment of an animal model, Fujita and Matsuyama examined
the methodology in the fungal selection of T. mentagrophytes
strains using the paper disk method, anthropophilic or
zoophilic, and arthroconidia or microconidia [66]. As a
result, no clear diﬀerence was noted between arthroconidia
and microconidia by MFID50 (50% minimal foot infec-
tious dose). In the histopathological examination, both the
anthropophilic and zoophilic strains infected the horny cell
layer, and the fungal invasions apparently continued for 6
months. Furthermore, the zoophilic strain infected a deeper
layer than the anthropophilic strain. Thus, the zoophilic
strain is thought to be more suitable for the animal model
than the anthropophilic strain.
3.2. Inoculation Size. No reports discussed a direct compari-
son using inoculation size in each animal model. Thus, we
surveyed previously published reports using T. mentagro-
phytes TIMM2789 (SM-110), which was selected most often
for the tinea pedis model.
The inoculation sizes in the paper disk method ranged
from 5 × 104 to 5 × 106 fungal cells/planta [66, 68–72].
In the bandage method, inoculation size was only 1 × 107
fungal cells/planta in all reports [67, 72–77]. However, even
if either method was selected, inoculum concentrations
applied to the animal should be considered in the concept
of the experiment described in the next section.
3.3. Duration of Infection and Treatment. The determination
of the infection period can be divided into two major
concepts. One is the concept of an inﬁnitely close association
with human pathology in order to accurately predict the
clinical eﬀects in humans. Another concept is that it should
be evaluated easily and quickly as a screening method for
candidate drugs. In the former, because it has been reported
that it took more than 26 weeks to spread over the sole [66],
the drug treatment was started 2 or 3 weeks after inoculation
[73–76]. In this case, the duration of drug treatment had
been set from 2 weeks to 4 weeks followed by the clinical
application period. In the latter case, the drug treatment
was started from 3 days after inoculation, and the duration
of treatment was for 3 or 7 days [71, 72]. In addition, the
duration of being ﬁxed by paper disk or bandage on the
planta pedis was 3 or 7 days in both cases.
3.4.PreparationMethodofTineaPedis. Thepaperdiskmeth-
od involved two types of paper disks, with or without
aluminum foil. A paper disk with aluminum foil was covered
with a piece of aluminum foil on one side (1.5mm thick by
8mm in diameter), while the other side held the inoculum
suspension. Any type of disc was wetted with 50µL of the
inoculum suspension and then ﬁxed on the planta pedis of
the guinea pig foot with elastic adhesive tape. The disc was
removed on the 3rd or the 7th day after infection.
The bandage method was as follows. Sheer Adhesive
Bandages (Band-Aid; Johnson & Johnson Co., Ltd., Tokyo,
Japan) were wetted with 100µL of the inoculum suspension
(1 × 108 conidia/mL) and then ﬁxed on the sole of an
animal’s foot with elastic adhesive tape. The Sheer Adhesive
Bandages were removed on the 3rd or the 7th day after
infection.
3.5. Pathology of Tinea Pedis Model. A detailed histopatho-
logical examination of the guinea pig model was reported by
FujitaandMatsuyama[66].WiththeanthropophilicstrainT.
mentagrophytes NTM-105, the infecting fungi were observed
in the upper two-thirds of the horny cell layer. Vertical
invasions to the deeper part of the horny cell layer next
to the granular layer were not observed at any time. Thus,
infection was superﬁcial, and no inﬂammatory response
was induced. The growing fungi spread horizontally in the
horny cell layer, and all parts of the plantar side of the foot
wereinfected.Clinicalsignsoferythema,hyperkeratosis,and
desquamation were absent. Such a silent infection persisted
throughout the observation period for 1 year.
In contrast to the anthropophilic strain T. mentagro-
phytes, the zoophilic strain T. mentagrophytes SM-110 in-
vaded the whole horny cell layer, and infecting fungi were
observed just above the granular layer. Vasodilatation in the
dermal papillae was noted. Two weeks after inoculation,
strong inﬂammatory responses were induced. Spongiosis
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epidermis.Inﬁltrationsofmononuclearandpolymorphonu-
clear cells were recognized under the vesicles and in the
perivascular areas. Exocytosis of these cells into the spongi-
otic epidermis was also present. However, the strong inﬂam-
matory response subsided rapidly within a week, and mild
responses persisted thereafter. Three weeks after inoculation,
massive growth of fungi in the hair follicles and cellular
inﬁltration became prominent in the skin of the dorsal
foot area. Clinically, severe signs of indurated erythema and
formation of thick scale and crust developed. All fungi were
recovered by culture from the infected feet throughout the
observation period for 6 months.
Although the anthropophilic strain T. mentagrophytes
NTM-105 had spread only in a small area during 3 weeks,
the infected area steadily spread to an approximately 19mm
radius at 13 weeks after inoculation. By contrast, the
zoophilic strain T. mentagrophytes SM-110 spread rapidly at
ﬁrst, reaching sites approximately 8mm from the point of
inoculationwithin4weeks,butthesubsequentrateofspread
wasmuchslower.Althoughthetwostrainsspreaddiﬀerently,
most areas of the plantar part were infected in 26 weeks.
3.6. Evaluation of Treatment with Tinea Pedis Model. Anti-
fungal eﬃcacy in the tinea pedis animal model was evaluated
with diﬀerent antifungals, such as butenaﬁne [73, 78, 79],
latoconazole [25, 80], naftiﬁne [78], tolnaftate [25, 76, 78,
80], clotrimazole [25, 76, 78, 80], bifonazole [25, 74, 78–
80], terbinaﬁne [67, 71–73], griseofulvin [67], lanoconazole
[70–72, 81], omoconazole [74], miconazole [75], NND-
502 (luliconazole) [72, 77], a combination drug of 0.2%
pyrrolnitrin and 0.4% clotrimazole [75], variotin [76],
phenyl-11-iodo-10-undecynoate [76], siccanin [76], KP-103
[81],andneticonazole[81].Ohmietal.comparedantifungal
eﬃcacy with two animal models, tinea corporis and tinea
pedis, using the same antifungal agents [80]. They suggested
that the conventional tinea corporis model produced on
the back of guinea pigs was sensitive to treatment with
several major topical antifungal agents, such as clotrimazole,
bifonazole, and tolnaftate, probably because of spontaneous
healing during the experimental period. However, the tinea
pedis model was much more resistant to treatment with
these drugs. The mycological cure rate of bifonazole 1%
cream in this report was 70%. In the clinical report, that of
bifonazole 1% cream for 4 weeks was 49.6% [82]. Thus, it is
possible to compare the eﬃcacy of each drug in tinea pedis
model; however, it may not accurately reﬂect the clinical
eﬀectivenessyetduetothediﬀerenceofmycologicalcurerate
between human and animal.
3.7. Evaluation of Relapse by Tinea Pedis Model. The relapse
after drug treatment was examined in the tinea pedis model,
which would not have healed spontaneously, unlike the tinea
corporis animal model, using the antifungal agents, such as
butenaﬁne[73,79],bifonazole[79],terbinaﬁne[73],KP-103
[81], neticonazole [81], lanoconazole [81], and NND-502
(luliconazole) [77]. The relapse of dermatophytosis, which
is highly dependent on environmental factors, is diﬃcult to
determineaccuratelyinclinicalpractice.Thus,veriﬁcationof
relapse using an animal model is very important research.
4. AnimalModel of Tinea Unguium
Invasion of the nail plate by a dermatophyte is referred to as
tinea unguium in humans. There are two main types of nail
involvement: invasive subungual (distal and proximal) and
superﬁcial white mycotic infection (leukonychia trichophyt-
ica). T. rubrum and T. mentagrophytes, respectively, are the
most common dermatophytes of this infection [4].
Therearefewreportsoftheanimalmodeloftineaungui-
um. One study used guinea pigs [73, 83], and the other used
rabbits [84]. This section describes the two animal models.
4.1. Animal Model of Tinea Unguium in Guinea Pigs. Uchida
et al. reported that T. mentagrophytes could infect the nail
when the tinea pedis model in guinea pigs would extend
the duration of the experiment [73]. Subsequently, the tinea
unguium model, which was modiﬁed by the above model,
was reported and evaluated drug eﬃcacy [83]. The method
and the evaluation results of drug eﬃcacy in tinea unguium
using guinea pigs were as follows.
The arthrospores of T. mentagrophytes SM-110 were
suspended, and the suspension was adjusted to give a con-
centrationof108 spores/mL.Twopaperdiskswereimmersed
by the fungal suspension and applied between the toes of
the hind paw (between the second third toes and between
the third and fourth toes) with a foam pad, then ﬁxed
with adhesive elastic tape (day 0 after infection). The disks
were removed on day 21 after infection. The antifungal
treatment, topical KP-103, amorolﬁne, and terbinaﬁne and
oral terbinaﬁne, started on day 60 after infection when the
invasion of T. mentagrophytes SM-110 into the nail was
conﬁrmed;treatmentcontinued for30 consecutivedays.The
therapeutic eﬃcacy of tinea unguium was evaluated by the
culture method to avoid the drug carryover eﬀects by using
dialyzed samples that have been digested by enzymes. In
the result, topical amorolﬁne and topical or oral terbinaﬁne
were ineﬀective even in terms of reducing the fungal
burden. In contrast, topical KP-103 signiﬁcantly reduced
the fungal burden in the infected nails compared with the
burdens found in the vehicle- and oral-terbinaﬁne-treated
groups.
This model was able to evaluate drug eﬃcacy by two
administration routes, oral and topical. Furthermore, this
model can prevent drug carryover in the recovery culture
and assess the pure viability of the fungi. However, this
evaluation method is applicable only to water-soluble drugs.
Thus, further consideration in the case of lipid-soluble drugs
is necessary.
4.2. Animal Model of Tinea Unguium in Rabbits. We estab-
lished an animal model using rabbits with conﬁrmed fungi
in the deep layer of the nail under an immunosuppressive
condition [84]. In this section, we describe the method and
results of the drug eﬃcacy of our model.6 Journal of Biomedicine and Biotechnology
In some preliminary studies, three points were con-
cluded: ﬁrst, microconidia were more suitable than arthro-
conidia with regard to infection rate; second, the postinfec-
tion period from the end of infection to nail sampling was
needed to maintain high infection rates; and third, adminis-
tration of an immunosuppressant was essential to make T.
mentagrophytes invade the nail to establish a reproducible
infection. Subsequently, we performed experiments aimed at
settingthesuitablepostinfectionperiod,andtheprotocolfor
this experiment was as follows.
The nails of rabbits were immunosuppressed with injec-
tions of methylprednisolone acetate intramuscularly prior to
application of 0.2mL of fungal suspension (108 microconi-
dia/mL) of T. mentagrophytes TIMM2789 at a site between
the lunula and the proximal nail fold. The nail plates of the
ﬁrst-to-third toes of the hind paw were wrapped together
with a gauze patch and ﬁnger cot, and 0.5mL of sterile
water was injected into the ﬁnger cot to produce a culture
environment around the nail that was seemed suitable for
fungal growth. This condition was maintained for the dura-
tion of the infection for 2 weeks with no other intervention.
The ﬁnger cot and the gauze patch were removed after
2 weeks of exposure, and this condition was maintained
d u r i n gf o r0 ,2 ,o r6w e e k sw i t h o u tﬁ n g e rc o ta n dg a u z e
patch; this was termed the postinfection period. After each
postinfection period was completed, the animals were sacri-
ﬁced, and the nails were removed from the paw and treated
histopathologically.
In the results, some of the infected nails became cloudy
on gross appearance, which was similar to the ﬁndings with
human onychomycosis. With a longer postinfection period,
these ﬁndings were fully conﬁrmed. On histopathological
examination, hyphae of T. mentagrophytes penetrated the
nail plate, and some invading fungi reached the nail bed. The
infectionrateinthesampleat0,2,and6weeksafterinfection
was 57%, 87%, and 93%, respectively. In addition, fungi
proliferated and moved distally into the nail plate depending
on the duration of infection. The presence of subungual
abscess with associated necrosis of the epithelium of the nail
bed or matrix was conﬁrmed near the fungi in the nail plate.
Aboveall,ahighinfectionratewasobtainedby2weeksinoc-
ulation with microconidia of T. mentagrophytes TIMM2789
and postinfection periods of more than 2 weeks were re-
quired.
Subsequently, the experiment for drug eﬃcacy was con-
ﬁrmed for the topical antifungal agents, 8% ciclopirox nail
lacquer and 5% amorolﬁne nail lacquer, using this model.
The therapeutic period was set as 4 weeks after a 2-week
infection period. The animals in the untreated control group
underwent the process of infection and removal of the
material used for this process, but they were not exposed
to the test agents. The next day after the last treatment, the
animals were sacriﬁced and the nails were removed from
the paw for histopathological and microbiological examina-
tions. In the microbiological examination, the infected nail
intended for evaluation using culture recovery was cut into
10 pieces in cross-sections, and each nail piece was cultured
on Sabouraud dextrose agar for 2 weeks at 28◦C. A nail piece
that had conﬁrmed fungal growth was assessed as culture
positive,andanailwithmorethanoneculture-positivepiece
was considered fungus positive.
In the results of microbiological examination, a statisti-
cally signiﬁcantly lower rate of culture positivity was found
in the 5% amorolﬁne nail lacquer group for comparing the
infection rate to that in both the control and 8% ciclopirox
nail lacquer groups. Additionally, when the rate of culture
positivity in the drug-treated groups was subtracted from
that in the nontreated group, the diﬀerences were 54.2% on
5% amorolﬁne nail lacquer and 8.3% on 8% ciclopirox nail
lacquer. This ﬁgure was similar in the clinical reports [85–
87].
This is the ﬁrst report of fungal behavior in the nail
plate in an experimental animal model of onychomycosis.
Our experimental animal model succeeded in encouraging
T. mentagrophytes to invade the deeper layers of the nail
plate. The ﬁndings in our model were similar to the clinical
diagnoses of the proximal subungual type (PSO). Further-
more, the eﬃcacy of this model was close to the clinical
cure rate. Further research using this model may be able to
clarify the pathogenesis of onychomycosis and contribute to
the development of drugs that match the clinical eﬃcacy.
5.Approachto AccuratelyEvaluate
the AntifungalAgent In Vivo
Thus, animal models have been introduced to simulate hu-
man skin diseases, as well as changes in disease, and have
presented diﬀerent ideas for antifungal evaluation. It is also
necessary to accurately evaluate the therapeutic eﬀects that
have been provided to create an environment in various
pathological ways [88–90].
In evaluating the eﬀectiveness of antifungal agents in
samples from animals and humans, it is necessary to pay
attention to the fact that the new medium can attenuate the
eﬀects of antifungal agents remaining in the skin sections as
has been reported in in vitro experiments [88], as well as
the culture results that have been reported in human skin
sections [89]. In addition, methods have been reported to
evaluate the eﬀects of antifungal agents in accordance with
the size of the expanding growth of fungal colonies [90].
Contributions have been made in the determination of in
vivo eﬀects of antifungal agents in combination with the
previous medium has been suggested. Already a new method
against onychomycosis was proposed by Nakashima et al.
[91]. This approach is expected to be useful for evaluating
the preliminary antifungal eﬀect.
6.Immunology
Anunderstanding ofthedefensemechanism ofhumans with
regard to a fungus is very important in order to create a der-
matophytosis animal model that shows high reproducibility
of human disease. The major problem faced by animal
models is the occurrence of spontaneous healing, which does
not occur in humans.
Dermatophyte colonization on the human skin is char-
acteristically limited to the dead keratinized tissue of theJournal of Biomedicine and Biotechnology 7
stratum corneum and results in a mild or intense inﬂam-
matory reaction. The fungi invade the horny layer which
lacks a speciﬁc immune system to combat the infection are
eliminated by skin turnover with subsequent desquamation.
Nevertheless, both humoral and cell-mediated reactions and
speciﬁc and nonspeciﬁc host defense mechanisms respond
and eventually eliminate the fungus.
Detailed research on the relationship between fungi and
immunity has been reviewed by Weitzman and Summerbell
[4]. Brieﬂy described below: (1) keratinases and glycopep-
tides are known as the two major classes of dermatophyte
antigens. Keratinases, produced by the dermatophytes to
enable skin invasion, elicit delayed-type hypersensitivity
(DTH) responses when injected intradermally into the
skin of animals. The protein portion of the glycopeptides
preferentially stimulates cell-mediated immunity (CMI),
whereas the polysaccharide portion preferentially stimu-
lates humoral immunity. However, antibodies produced by
humoral immunization do not help eliminate the infection
since the highest level of antibodies is found in those patients
with chronic infections. Rather, the development of CMI,
which is correlated with DTH, is usually associated with
a clinical cure and ridding the stratum corneum of the
oﬀending dermatophyte. (2) Infections by anthropophilic
fungi like T. rubrum often elicit less of an inﬂammatory
response and are less likely to elicit an intense DTH response
than infections caused by geophilic or zoophilic dermato-
phytes which characteristically evoke an intense inﬂamma-
tory reaction. Much of this inﬂammation is produced by the
activated lymphocytes and macrophages which are involved
in the DTH reaction to the trichophytin glycopeptides. (3)
Enhanced proliferation of the skin in response to the inﬂam-
mation may be the ﬁnal mechanism that removes the fungus
from the skin by epidermal desquamation. (4) Mannan, a
glycoproteincomponent ofthe fungalcellwall,maysuppress
the inﬂammatory response especially in atopic or other
persons susceptible to the mannan-induced suppression of
CMI. Incubation of puriﬁed T. rubrum mannan (TRM)
inhibited the lymphocyte proliferation response to mitogens
andvariousantigenicstimuli.TRMalsoinhibitskeratinocyte
proliferation, thus slowing epidermal turnover and allowing
for a more persistent chronic infection. (5) Chronic der-
matophytosismaybecausedbytheanthropophilicformofT.
mentagrophytes, T. mentagrophytes var. interdigitale (T. inter-
digitale). Primary chronic trichophytosis may be associated
with defective phagocytosis of peripheral blood leukocytes
and that this defect is probably caused by the fungus itself.
Keywords to note are keratinases, glycopeptides, CMI,
DTH, Mannan, phagocytosis of peripheral blood leukocytes,
and skin turnover. Thus, the factors of fungi such as ker-
atinase and glycopeptides including Mannan induce human
CMI which is specially correlated with DTH, phagocytosis of
peripheral blood leukocytes, and inhibition of skin turnover.
In other words, the loss or decrease of these host’s defense
mechanisms lead to unsuccessful elimination of the fungi
and may cause chronic dermatophytosis. We suggest that
future experiments will be required on the relationship
between fungi and immunity to overcome the challenges of
the current animal model.
7.AnimalEthics
Because reproduction of human pathophysiology is hardly
diﬃcult in an in vitro experiment, the experiments using
animals are necessary for the elucidation of unknown patho-
genesisandthedevelopmentofsigniﬁcantdrugsforpatients.
For now, animals will undergo invasive procedures and
may bleed for several weeks after surgical intervention or
another way in order to make a model of dermatophytosis
which must be essentially regarded as a category of chronic
inﬂammation. Thus, we will have to plan an experiment that
should follow the spirit of the 3Rs: reduction, reﬁnement,
and replacement [92]. All experimental designs should be
reviewed by the Institutional Animal Care and Use Commit-
tees (IACUC) to determine whether the protocol follows the
experiment facility guidelines or national guidelines [93].
8. Conclusion andFutureProspects
Using the main dermatophytosis animal model for tinea
corporis, tinea pedis, and tinea unguium to elucidate the
pathophysiology of human dermatophytosis and to evaluate
antifungal agent eﬃcacy, various experiments have been
conducted. Reports of the tinea corporis model have been
most published as comparisons of other dermatophytosis
models; however, a satisfactory model has not been reported
with regard to reproducibility and usefulness in the evalua-
tion of drug eﬃcacy because of spontaneous healing. Thus,
antifungal eﬃcacy may be estimated as greater than the
actual eﬀect. For nonspontaneous healing, the tinea pedis
modelhasbeensaidthatthebestmodelfordermatophytosis.
This model conﬁrmed that drug eﬃcacy was dependent on
MIC values. On the other hand, intractable tinea pedis is
observedinhumans.Thepathologyofintractabletineapedis
cannot be reproduced in this model, yet. The eradication of
onychomycosis is important because onychomycosis causes
the recurrence of tinea pedis or the spread of infection.
However, there is no animal model that can reproduce all
types of tine unguium in humans.
These diﬃculties in the establishment of a dermato-
phytosis animal model are thought to be attributed to the
diﬀerences between animals and humans: the skin structure,
immune system, and causative fungi. The diﬀerences in the
skin structure, such as the thickness of the epidermis and
horny cell layer and the number of follicles, may determine
whether fungi can attach to the skin surface because experi-
mentally infection was performed on the xenografted guinea
pig skin but not on the skin of xenograft nude mice. Com-
plex immune functions against organisms through fungal
attachment are activated in order to eliminate fungi by CMI
involved in DTH and skin turnover. Thus, the spontaneous
healing observed in the animal model is the host’s normal
response. Considering the situation that many challenges
remain in animal models, however, the loss or decrease in
normal immune functions may be necessary in order to
create a reproducible animal model. The characteristics of
the causative organisms are important in the animal model
because the causes to be eliminated are antigens against
metabolic products by fungi and a part of the fungus itself.8 Journal of Biomedicine and Biotechnology
With the rapid development of molecular biology in recent
years has come the gradual expansion of genetic studies of
Trichophyton spp. [94]. This body of research will enable
the transformation of fungi. The creation of a transformed
strain that causes lesions similar to humans, but also leads to
understandinghumandisease,canleadtoproperveriﬁcation
of the drug eﬀect.
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